Cybrexa Therapeutics to Present at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

NEW HAVEN, Conn., Sept. 28, 2021 (GLOBE NEWSWIRE) —

Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform, announced today that it will present the results of a preclinical study of CBX-12 (alphalex™-exatecan), the company’s lead therapeutic candidate for solid tumors, at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 7-10, 2021.

Cybrexa Therapeutics Associate Director of Biology Sophia Gayle will present results of a study evaluating the efficacy of CBX-12 in combination with PD-1- and CTLA4-targeted immune checkpoint inhibitors in preclinical cancer models. The presentation will be viewable beginning at 9:00AM ET on Thursday, October 7, to registered attendees of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.

CBX-12 is a novel treatment for solid tumors that includes a highly potent topoisomerase I inhibitor payload that is in the same class as the payloads used by antibody-drug conjugates (ADCs) ENHERTU® and TRODELVY™. In contrast to these ADCs, CBX-12 is able to target cancer cells independent of antigen expression, which could greatly expand the addressable patient populations. In May, Cybrexa initiated a Phase 1/2 clinical trial to evaluate CBX-12 in patients with advanced or metastatic refractory solid tumors to determine its safety and tolerability, maximum tolerated doses and dose limiting toxicities, and to establish the recommended Phase 2 dose.

Additional meeting information is available on AACR’s website.

About the alphalex™ Technology Platform
The Cybrexa alphalex™ technology platform – which consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent (payload) – enables antigen-independent targeting of tumors and intracellular delivery of highly potent anticancer therapies, creating therapeutics that can revolutionize the standard of care. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. View a video of the mechanism of action of the technology at

About Cybrexa
Cybrexa is a privately-held biotechnology company dedicated to developing next-generation tumor-targeted cancer therapies using its alphalex™ platform. The Company’s lead candidate, CBX-12, an alphalex™-exatecan conjugate, has entered a Phase 1/2 clinical trial in patients with advanced or metastatic solid tumors. Cybrexa also has other preclinical toxin conjugate programs as well as synthetic lethality programs. Cybrexa was founded by physician-scientists and has an experienced management team that has built numerous successful life sciences companies. For more information about Cybrexa, please visit


Cybrexa Therapeutics
Lisa Rehm
Email: [email protected]

Westwicke, an ICR Company
Investor Relations
Stephanie Carrington
Tel: 646-277-1282
Email: [email protected]

Media Relations
Mark Corbae
Tel: 203-682-8288
Email: [email protected]